Cogent Biosciences Inc’s recently made public that its Chief Commercial Officer Pinnow Cole acquired Company’s shares for reported $0.33 million on Jan 14 ’25. In the deal valued at $7.60 per share,43,750 shares were bought. As a result of this transaction, Pinnow Cole now holds 45,848 shares worth roughly $0.37 million.
Needham downgraded its Cogent Biosciences Inc [COGT] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who decreased its forecast for the stock in late February from “an Outperform” to “a Neutral”. Citigroup began covering COGT with “Buy” recommendation on February 08, 2024. Wedbush revised its rating on December 11, 2023. It rated COGT as “a Neutral” which previously was an “an Outperform”.
Price Performance Review of COGT
On Friday, Cogent Biosciences Inc [NASDAQ:COGT] saw its stock fall -1.11% to $8.00. Over the last five days, the stock has lost -2.20%. Cogent Biosciences Inc shares have risen nearly 2.56% since the year began. Nevertheless, the stocks have fallen -6.87% over the past one year. While a 52-week high of $12.61 was reached on 01/30/25, a 52-week low of $5.73 was recorded on 01/13/25. SMA at 50 days reached $8.35, while 200 days put it at $9.29.
Levels Of Support And Resistance For COGT Stock
The 24-hour chart illustrates a support level at 7.85, which if violated will result in even more drops to 7.70. On the upside, there is a resistance level at 8.19. A further resistance level may holdings at 8.38. The Relative Strength Index (RSI) on the 14-day chart is 41.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.49, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.15%. Stochastics %K at 7.34% indicates the stock is a buying.
The most recent change occurred on December 08, 2023 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $18 price target.
